Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)

BACKGROUND. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. PATIENTS AND METHODS. One thousand and five hundred patients with early breast cancer were en...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Huovinen, Riikka, Jukkola-Vuorinen, Arja, Tanner, Minna, Kokko, Riitta, Ahlgren, Johan, Auvinen, Päivi, Saarni, Outi, Helle, Leena, Villman, Kenneth, Nyandoto, Paul, Nilsson, Greger, Leinonen, Mika, Kataja, Vesa, Bono, Petri, Lindman, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894716/
https://www.ncbi.nlm.nih.gov/pubmed/23957715
http://dx.doi.org/10.3109/0284186X.2013.820840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894716/
https://www.ncbi.nlm.nih.gov/pubmed/23957715
http://dx.doi.org/10.3109/0284186X.2013.820840

Ejemplares similares